DNA Damage Repair Inhibitor for Breast Cancer Treatment

Area of Science:

• Genetics and Oncology
• Molecular Biology
• Pharmacology

Background:

• Cancer is a genetic disorder driven by accumulated DNA damage and impaired DNA damage repair (DDR) pathways.
• Loss of DDR function leads to increased genomic instability and replication stress, hallmarks of cancer.
• Synthetic lethality offers a novel therapeutic strategy by exploiting these DDR pathway deficiencies.

Purpose of the Study:

• To review the clinical application and ongoing research of DNA damage repair (DDR) inhibitors, focusing on poly-(ADP-ribose) polymerase (PARP) inhibitors.
• To explore the concept of synthetic lethality and its expansion beyond BRCA mutations for PARP inhibitor efficacy.
• To highlight emerging research areas including novel biomarkers for homologous recombination deficiency (HRD), drug combinations, and resistance mechanisms.

Main Methods:

• Review of clinical trial data for PARP inhibitors in patients with BRCA1/2 germline mutations (gBRCA1/2mt).
• Analysis of preclinical and clinical studies investigating combinations of DDR inhibitors with other anticancer agents.
• Examination of research into immune-modulatory effects of DDR inhibitors and their combination with immune checkpoint inhibitors.

Main Results:

• PARP inhibitors demonstrate significant clinical benefits in breast and ovarian cancers with gBRCA1/2mt.
• Active research is identifying new HRD markers beyond BRCA1/2 and optimizing patient selection for DDR inhibitors.
• Combinations of DDR inhibitors with chemotherapy, targeted agents, and immunotherapy are under investigation.

Conclusions:

• DDR inhibitors, particularly PARP inhibitors, represent a promising class of anticancer drugs based on synthetic lethality.
• Future research should focus on identifying broader HRD markers, understanding resistance mechanisms, and optimizing combination therapies.
• Standardized methods for detecting HRD are crucial for the clinical implementation of DDR inhibitors.